NEW HAVEN, Conn.--CuraGen and Genentech announced that their drug research collaboration will continue for at least two-and-a-half-years. The deal, struck up in 1997, applies CuraGen's high-throughput functional genomic technologies and disease expertise to discovery of protein therapeutics and antibodies.